-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 28, the official website of the State Food and Drug Administration showed that Xinlitai's cefoxitin sodium for injection passed the consistency evaluation and was the third in China
.
According to data from Meinenet, the peak sales of this product in China's public medical institutions exceed 5.
5 billion yuan, which has declined in recent years, but there will still be a sales scale of more than 2.
5 billion yuan in 2020
.
Source: Cefoxitin on the official website of the State Drug Administration is a cephalosporin antibacterial drug that kills bacteria by inhibiting the synthesis of bacterial cell walls.
It is suitable for infections caused by bacteria that are sensitive to this product, including upper and lower respiratory tract infections, urinary tract infections, peritonitis, and pelvic cavity.
internal infections, gynecological infections, endocarditis
.
At present, more than 50 domestic companies have production approvals for cefoxitin sodium for injection.
According to data from Meinenet, this product is used in the terminals of urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
The sales peak of over 5.
5 billion yuan, sales have declined in recent years, but there will still be a sales scale of more than 2.
5 billion yuan in 2020
.
Judging from the competitive landscape of manufacturers of this product in the first half of 2021, TOP3 companies Yangzijiang, Haikou Pharmaceutical, and Sinopharm Zhijun all accounted for more than 10% of the market share, with Yangzijiang dominating the market
.
More than a dozen companies submitted supplementary applications for the consistency evaluation of cefoxitin sodium for injection.
Among them, Yangtze River was the first to have reviewed it, Shandong Luoxin Pharmaceutical Co.
, Ltd.
followed closely, and Xinlitai was the third company to review.
The products of other companies are still under review.
Under review
.
According to data from Meinenet, since this year, Xinlitai, including cefoxitin sodium for injection, has passed or deemed to have passed the consistency evaluation of 8 varieties
.
From 2021 to the present, the source of some over-evaluated varieties of Xinlitai: Meinenet MED2.
0 China Drug Evaluation Database.
From the perspective of medication route, 4 of the 8 over-evaluated varieties are injections; from the treatment category, of the 8 over-evaluated varieties There are 4 types of anti-infective drugs for systemic use, 2 types of anti-tumor drugs, and 2 types of anticoagulant drugs
.
Source: Minainet database, official website of the State Food and Drug Administration, etc.
Note: Statistics are as of December 28.
If there are any omissions, please correct me!
.
According to data from Meinenet, the peak sales of this product in China's public medical institutions exceed 5.
5 billion yuan, which has declined in recent years, but there will still be a sales scale of more than 2.
5 billion yuan in 2020
.
Source: Cefoxitin on the official website of the State Drug Administration is a cephalosporin antibacterial drug that kills bacteria by inhibiting the synthesis of bacterial cell walls.
It is suitable for infections caused by bacteria that are sensitive to this product, including upper and lower respiratory tract infections, urinary tract infections, peritonitis, and pelvic cavity.
internal infections, gynecological infections, endocarditis
.
At present, more than 50 domestic companies have production approvals for cefoxitin sodium for injection.
According to data from Meinenet, this product is used in the terminals of urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions).
The sales peak of over 5.
5 billion yuan, sales have declined in recent years, but there will still be a sales scale of more than 2.
5 billion yuan in 2020
.
Judging from the competitive landscape of manufacturers of this product in the first half of 2021, TOP3 companies Yangzijiang, Haikou Pharmaceutical, and Sinopharm Zhijun all accounted for more than 10% of the market share, with Yangzijiang dominating the market
.
More than a dozen companies submitted supplementary applications for the consistency evaluation of cefoxitin sodium for injection.
Among them, Yangtze River was the first to have reviewed it, Shandong Luoxin Pharmaceutical Co.
, Ltd.
followed closely, and Xinlitai was the third company to review.
The products of other companies are still under review.
Under review
.
According to data from Meinenet, since this year, Xinlitai, including cefoxitin sodium for injection, has passed or deemed to have passed the consistency evaluation of 8 varieties
.
From 2021 to the present, the source of some over-evaluated varieties of Xinlitai: Meinenet MED2.
0 China Drug Evaluation Database.
From the perspective of medication route, 4 of the 8 over-evaluated varieties are injections; from the treatment category, of the 8 over-evaluated varieties There are 4 types of anti-infective drugs for systemic use, 2 types of anti-tumor drugs, and 2 types of anticoagulant drugs
.
Source: Minainet database, official website of the State Food and Drug Administration, etc.
Note: Statistics are as of December 28.
If there are any omissions, please correct me!
